Call Us: (1) 608 441-2729 - Email Us firstname.lastname@example.org
M2SR: The Vaccine
Board of Directors
Clinical Advisory Board
News and opinions
The Flu and You – by Kelsey Kaustinen, ddn Senior Editor
February 28, 2013
Share this Story
Comments are closed.
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults
FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference
FluGen to Present at Baird’s 2021 Global Healthcare Conference
FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus
(c)2016 FluGen, Inc. All rights reserved.
Back to Top